07.07.2015

Bayer HealthCare launches Aspirin® dragees, created by reinventing Aspirin® 500mg tablets for pain relief

The new Aspirin uses a micro-active technology to relief pain two times faster than before

Bucharest, July 7th, 2015 – An old proverb says that life is too short for waiting. In today's world, where everything happens fast-paced, no one wants to wait for anything, and much less for pain relief. This is why Bayer HealthCare launches new Aspirin®, which has been clinically proven to relieve pain twice faster than traditional Aspirin® tablets.*1
 
 
Since the introduction of the "miracle drug" that was Aspirin® back in 1899, Bayer HealthCare has maintained its commitment to innovation. The new Aspirin® is the result of over a hundred years of science and discovery, so that you can resume your daily activities, instead of suffering, and this two times faster than before. *1
 
 
By using a proprietary micro-active technology, the new Aspirin® is one of the most important innovations in the brand's history. With its new package, fully green and the good looking and innovativeblisters, portable, clover-shaped, it will replace Aspirin® 500 mg tablets on shelves across the country.
 


"In today's world, where everything happens at brisk speeds, analgesia's speed is as important as product strength," said Emilio Bellantoni, Country Head Bayer Consumer Care Division Romania - Bulgaria - Moldova. "The new Aspirin® enables us to provide our customers with the reliable analgesic effect of Aspirin® at a greater speed than ever before, which will allow them to resume their hectic lives without pain."
 


Aspirin® uses a new patented technology that diminishes particles of Aspirin 500 mg tablets into microparticles whose dimensions are about 10% that of conventional tablets 500 mg Aspirin. The technology combines reduced particle size with the rapidly disintegrating tablets, with the result that new Aspirin® dissolves six times faster than before (as fast as the drug Aspirin® plus C effervescent tablets), easily entedrs the bloodstream [1] and relieves pain twice faster than conventional Aspirin® tablets .1
 
The new Aspirin® is now available in pharmacies across the country, in packs of 20 tablets. For more information on the new Aspirin®, please visit aspirin.ro.


 
On the new Aspirin®


The new Aspirin® tablets will replace the previous version of Aspirin® 500 mg tablets of Bayer SRL. The new Aspirin® achieves symptomatic treatment of fever and / or mild to moderate pain, such as headaches, flu syndrome, dental  and muscle pain. It has been demonstrated the new Aspirin® achieves a statistically significant improvement of pain relief compared to placebo for a period of up to six hours. [2] The recommended dosage and maximum dose are specified in the package insert, which should be read and followed before administering the product with liquids, as mentioned. For children under the age of 12 years (weighing less than 40 kg), it should not be administered without a prescription.
 
The safety profile of acetylsalicylic acid, the active ingredient of the new Aspirin® is one of the most exhaustively researched medicines in the world. With over 115 years of recorded evidence on safety and efficacy, it has been tested over the lives of generations. Recently published meta-analyzes of 145 clinical trials, representing over 32,000 patients and 20 years of research have confirmed the general gastrointestinal (GI) safety of acetylsalicylic acid for short-term treatment of mild to moderate pains and fever caused by colds or flu, when used as directed, demonstrating a reduced incidence of GI adverse reactions minor and no serious drug-related adverse reactions. [3] [4]


 
Forward-looking statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to confirmthem to future events or developments.
 
Advertising visa no. 111 / 09.04.2015

1. Voelker M, Hammer M. Dissolution and pharmacokinetics of a novel micronized aspirin formulation. Inflammopharmacology. 2012 Aug;20(4):225-31
2. Date din dosar
3.  Lanas, et al. Short-Term Aspirin Use for Pain and Cold: Gastrointestinal Adverse Effects. Drugs in R&D. 2011; 11: 277-288
4.  Baron JA, et al.  Gastrointestinal Adverse Effects of Short term Aspirin use:  A Meta-analysis of Published Randomized Controlled Trials.  Drugs in R&D 2013;13(1):9-16